You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 503 Clinical activity of ICT01, an anti-BTN3A-targeted, γ9δ2-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
503 Clinical activity of ICT01, an anti-BTN3A-targeted, γ9δ2-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to September 2024

AbstractFullPdf
Nov 2021469038
Dec 202182017
Jan 202274020
Feb 202282019
Mar 2022140019
Apr 202296012
May 202280017
Jun 202258018
Jul 20222403
Aug 20225406
Sep 202252014
Oct 20225009
Nov 20222206
Dec 20224403
Jan 20233603
Feb 20235409
Mar 20235208
Apr 20233806
May 20232809
Jun 20232003
Jul 202340019
Aug 20233203
Sep 20234203
Oct 20234409
Nov 20236607
Dec 20234804
Jan 20243602
Feb 20243804
Mar 20244006
Apr 20244808
May 20245006
Jun 20244009
Jul 20245204
Aug 20243403
Sep 20243809
Total22030335